DENVER--(BUSINESS WIRE)--Vivos Therapeutics, a world leader in the treatment of obstructive sleep apnea (OSA), today announced it has entered into an exclusive licensing agreement with VSB, LLC, an operating company owned by Dr. Willis Pumphrey, founder of ClearCorrect, a major Vivos investor and member of the Vivos board of directors.
Under the terms of the agreement, Vivos will leverage VSB financial and personnel resources as it expands its Vivos Breathing Wellness Centers into select markets, including in Colorado and nationwide. Vivos currently owns and operates centers in Johnstown and Highlands Ranch, Colorado. Two additional facilities, Cherry Creek (Denver) and Colorado Springs, will join the most recently opened facility in Arvada this month.
The Vivos System is a breakthrough technology and treatment for OSA, and may be the first viable long-term solution to address a major root cause of the condition: an underdeveloped or obstructed airway. While the vast majority of OSA solutions treat the symptoms through either pressure or force, the Vivos appliance gently remodels the upper airway by gradually developing/repositioning the jaws, thus restoring healthy sleep and breathing. While other OSA treatment modalities, such as CPAP, require lifetime use and nightly wear, the Vivos System treatment typically lasts 12 to 24 months, and can allow some patients to avoid further clinical intervention.
"We’ve already had thousands of patients who have experienced the benefits of Vivos technology, and this agreement with VSB and Dr. Pumphrey brings us the potential to help tens of thousands more,” said Kirk Huntsman, CEO, Vivos. "By aligning with VSB, we’re able to extend the footprint and reach of Vivos Breathing Wellness Centers into major metropolitan markets across the country, and help improve even more lives.”
Pumphrey, a world-renowned entrepreneur in aligner orthodontics, was recently appointed to the Vivos board of directors. He has more than 30 years of experience with cosmetic, restorative and implant dentistry, as well as orthodontics. In August 2017, Pumphrey sold ClearCorrect to Straumann Group, a global leader in dental implant solutions, for $150 million, in order to co-venture with Vivos and join its board of directors.
For more information about Vivos, please click here.
Founded in 2016, Vivos Therapeutics combines breakthrough technology for specially designed oral appliances with proprietary clinical protocols for obstructive sleep apnea (OSA) treatment that can restore and enhance the human airway. Because its patented FDA Class I and II medical devices are thought to be the first treatment that addresses the root causes of OSA, Vivos can improve the airway so that further clinical intervention may no longer be required in some cases. Other treatments for this insidious and dangerous condition require lifetime treatment, which has a significant impact on U.S. healthcare costs. Because the Vivos System is all-natural, non-invasive and non-pharmaceutical, many more patients will be able to receive treatment from the 750+ (and growing) independent providers who have been trained and certified in the Vivos methodology and who have already treated more than 8,000 patients. The company also is creating Vivos Breathing Wellness Centers in major metro areas, working with licensed and trained local medical and dental professionals. For more information, visit vivoslife.com.